市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Imunon, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | 4.0 |
| 价格波动 | 2.2 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | -2.5 |
| 相对估值 | NA |
| 财务健康 | -4.9 |
| 宏观环境 | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | 0.53 |
|
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 5.19% |
| 机构持股比例 | 1.15% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Riverview Capital Advisers, Llc | 30 Jun 2026 | 34,364 |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| FALLER DOUGLAS VINCENT | 1.24 | - | 27,833 | 34,513 |
| LINDBORG STACY | 1.24 | - | 2,603 | 3,228 |
| TARDUGNO MICHAEL H | 1.24 | - | 6,821 | 8,458 |
| 累积净数量 | 37,257 | |||
| 累积净值 ($) | 46,199 | |||
| 累积平均购买 ($) | 1.24 | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| FALLER DOUGLAS VINCENT | 职员 | 23 Oct 2026 | 获得 (+) | 27,833 | 1.24 | 34,513 |
| LINDBORG STACY | 职员 | 23 Oct 2026 | 获得 (+) | 2,603 | 1.24 | 3,228 |
| TARDUGNO MICHAEL H | 职员 | 23 Oct 2026 | 获得 (+) | 6,821 | 1.24 | 8,458 |
投资组合